Posters

Enhancing intermediate vision and patient satisfaction by combining an enhanced depth-of-focus IOL and a trifocal IOL models with different add powers

Poster Details

First Author: C.Lindel GERMANY

Co Author(s): F. Kretz   D. Breyer   H. Kaymak   S. Abdassalam   M. Muller   G. Auffarth   M. Gerl  

Abstract Details

Purpose:

To evaluate the refractive & functional results, patient satisfaction and defocus curve after implantation of a trifocal enhanced depth of focus (EDOF) intraocular lens in the distance dominant eye and a trifocal intraocular lens (trifocal) in the near dominant eye.

Setting:

Augenärzte Gerl, Kretz & Kollegen, Augenklinik Ahaus & Augentagesklinik Rheine, Ahaus, Germany

Methods:

In a prospective study cataract patients received the EDOF (AT LARA 829, Carl Zeiss Meditech, Germany) in their distance dominant eye and trifocal (AT LISA 839, Carl Zeiss Meditech, Germany) in their near dominant eye. Pre- and postoperative, monocular and binocular functional results (CDVA, UDVA, DCIVA [90cm, 80cm, 60cm], DCNVA, UNVA, Defocus curve; [logMAR]) refractive outcome, Halo and Glare Simulator and patient satisfaction score were evaluated.

Results:

55% of patients had a distance dominant right eye. Median postoperative spherical equivalent for the EDOF and the trifocal eyes was 0.00 D (0.13) and 0.00 D (0.28), respectively. Binocular UDVA, CDVA, DCNVA were -0.05 (0.07), 0.00 (0.06), 0.11 (0.16) with an DCIVA in 90cm, 80cm and 60 cm of -0.26, 0.05 and -0.08.Binocular defocus curve analysis show a stable visual acuity of >0.05 between 0.5 D to -2.5 D.

Conclusions:

The Mix & Match approach with a EDOF trifocal IOL in the distance dominant eye and a trifocal IOL in the near dominant eye seems to get better results for intermediate visual acuity while offering patients a higher degree of spectacle independency.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a competing company., ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented., ... receives consulting fees, retainer, or contract payments from a competing company